BVF Inc’s enGene Therapeutics Warrants ENGNW Stock Holding History

BVF Inc’s Portfolio ENGNW Stock Details ENGNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$274K	Hold	945,402	–	–	0.01%	44
2026 Q1	$2.49M	Hold	945,402	–	–	0.08%	41
2025 Q4	$2.4M	Hold	945,402	–	–	0.08%	41
2025 Q3	$681K	Hold	945,402	–	–	0.03%	45
2025 Q2	$586K	Hold	945,402	–	–	0.02%	43
2025 Q1	$605K	Hold	945,402	–	–	0.02%	50
2024 Q4	$804K	Hold	945,402	–	–	0.03%	52
2024 Q3	$804K	Hold	945,402	–	–	0.02%	52
2024 Q2	$1.31M	Hold	945,402	–	–	0.04%	55
2024 Q1	$4.92M	Hold	945,402	–	–	0.14%	48
2023 Q4	$804K	Buy	+945,402	New	+$727K	0.02%	68

Other funds holding ENGNW

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

BVF Inc's ENGNW Position: Q2 2026 in Review

BVF Inc held its enGene Therapeutics Warrants (ENGNW) position steady in Q2 2026 at 945,402 shares worth $274K. The position accounts for 0.01% of the portfolio, ranked #44.

BVF Inc first reported a position in ENGNW in Q4 2023 and has held it in 11 quarters since. The position peaked at $4.92M in Q1 2024. 11 funds tracked by Wall St. Rank hold ENGNW as of Q2 2026.

BVF Inc held 945,402 shares of enGene Therapeutics Warrants worth $274K as of Q2 2026.
BVF Inc left its enGene Therapeutics Warrants share count unchanged in Q2 2026.
enGene Therapeutics Warrants made up 0.01% of BVF Inc's portfolio in Q2 2026, its #44 holding.
BVF Inc first reported a position in enGene Therapeutics Warrants in Q4 2023 and has held it in 11 quarters since.
BVF Inc's enGene Therapeutics Warrants position peaked at $4.92M in Q1 2024.
11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q2 2026.

Based on BVF Inc's 13F filing for Q2 2026, filed 14 Aug 2026.